Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial

Abstract Background Preoperative chemoradiotherapy (PCRT) followed by surgery and adjuvant chemotherapy is the current standard treatment for stage II/III rectal cancer. However, radiotherapy in the pelvic area is commonly associated with complications such as anastomotic leakage, sexual dysfunction...

Full description

Bibliographic Details
Main Authors: Jii Bum Lee, Han Sang Kim, Inkyung Jung, Sang Joon Shin, Seung Hoon Beom, Jee Suk Chang, Woong Sub Koom, Tae Il Kim, Hyuk Hur, Byung Soh Min, Nam Kyu Kim, Sohee Park, Seung-Yong Jeong, Jeong-Heum Baek, Seon Hahn Kim, Joon Seok Lim, Kang Young Lee, Joong Bae Ahn
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Trials
Subjects:
Adjuvant chemotherapy
Clinical trial
FOLFOX
Locally advanced rectal cancer
Total mesorectal excision
Online Access:http://link.springer.com/article/10.1186/s13063-020-04266-6

Internet

http://link.springer.com/article/10.1186/s13063-020-04266-6

Similar Items